Experimental cancer combo trial halted early – what it means for patients
NCT ID NCT04278144
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial tested a new drug called BDC-1001, alone or with the immunotherapy nivolumab, in 175 people with advanced HER2-positive cancers (like breast, colorectal, and stomach cancers) that had stopped responding to other treatments. The study aimed to check safety and find the right dose, but it was terminated early, so full results are not available. The approach tries to stimulate the immune system to attack cancer cells, but it is still experimental.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BDC-1001 (an immune-stimulating antibody conjugate) and nivolumab (Opdivo, an immunotherapy)
What this could lead to
If successful, this could point toward a new treatment option for advanced HER2-positive cancers that have stopped responding to standard therapies.
What could go wrong
This was a very early (Phase 1/2) trial that was terminated, so results are limited. The combination may cause significant immune-related side effects, and it is unclear if it will work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, Songpa-gu, 05505, South Korea
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
-
Hospital Universitario 12 de Octubre
Madrid, Madrid, 28041, Spain
-
Hospital Universitario Ramón y Cajal
Madrid, Madrid, 28034, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, Catalonia, 08035, Spain
-
Hospital del Mar
Barcelona, Catalonia, 08003, Spain
-
Institut Bergonie
Bordeaux, 33076, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Institut Paoli Calmettes
Marseille, 13009, France
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
Samsung Medical Center
Seoul, Gangnam-gu, 06351, South Korea
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 13620, South Korea
-
South Texas Accelerated Research Therapeutics
San Antonio, Texas, 78229, United States
-
Stanford University
Palo Alto, California, 94304, United States
-
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
The University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States